Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB122 DDI Study with Rabeprazole in Healthy Participants
NCT06264440Phase 1Completed
- Sponsor
- Biogen
- Start
- Feb 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BIIB122 in Parkinson's disease (PD), sponsored by Biogen. Primary endpoints: Maximum Observed Concentration, Area Under the Concentration-Time Curve From Time Zero to Time of the Last Measurable Concentration and 1 more. Started Feb 2024; status: completed.
02
Drugs
BIIB122
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06264440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06264440.